Zymeworks (ZYME) Income from Continuing Operations (2021 - 2026)
Zymeworks recorded quarterly Income from Continuing Operations of 44162000.0 in Q1 2026, down 7.17% quarter-over-quarter from 41209000.0 in Q4 2025, and down 95.1% year-over-year from 900586515.32 in Q1 2025.
Zymeworks' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 44162000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 95.1% year-over-year to 44162000.0; the TTM figure through Mar 2026 stood at 102656000.0 (up 9.7% YoY), while the FY2025 annual figure was 81130000.0, up 33.88% from the prior year.
- Income from Continuing Operations came in at 44162000.0 for Q1 2026 at Zymeworks, down from 41209000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 309431000.0 in Q4 2022 to a low of 72625000.0 in Q1 2022.
- A 5-year average of 14254117.65 and a median of 29850000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations soared 890.33% in 2022 and tumbled 104.68% in 2023, its largest moves.
- Zymeworks' Income from Continuing Operations stood at 309431000.0 in 2022, then sank by 104.68% to 14482000.0 in 2023, then slumped by 62.31% to 23506000.0 in 2024, then sank by 75.31% to 41209000.0 in 2025, then retreated by 7.17% to 44162000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 44162000.0, 41209000.0, and 19602000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -44.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.16 Mn |
| Dec 31, 2025 | -41.21 Mn |
| Sep 30, 2025 | -19.60 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -23.51 Mn |
| Sep 30, 2024 | -29.85 Mn |
| Jun 30, 2024 | -37.69 Mn |
| Mar 31, 2024 | -31.65 Mn |
| Dec 31, 2023 | -14.48 Mn |
| Sep 30, 2023 | -28.69 Mn |
| Jun 30, 2023 | -51.15 Mn |
| Mar 31, 2023 | -24.35 Mn |
| Dec 31, 2022 | 309.43 Mn |
| Sep 30, 2022 | -47.85 Mn |
| Jun 30, 2022 | -64.62 Mn |
| Mar 31, 2022 | -72.63 Mn |
| Dec 31, 2021 | -39.15 Mn |
| Sep 30, 2021 | -60.58 Mn |